BS stands for Blue Shield
Dr. Esserman ordered the Oncotype DX Test for me over 1 month ago (see post “What is Oncotype DX?”) Today I received Blue Shield’s denial letter stating: “A physician advisor has reviewed the information provided and determined that the requested service would not be covered as medically necessary under the terms of this health plan per […]
What Is Oncotype DX?
Oncotype DX is the first clinically validated commercial genomic assay for patients with DCIS. Oncotype DX reveals the underlying biology that can help guide DCIS treatment decisions by predicting the risk of any local recurrence of breast cancer (DCIS or invasive) and the risk of local invasive carcinoma and allowing for personalized treatment based on […]